Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2025-03-21 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团关于召开2024年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2024 Annual General Meeting (AGM) of the company, including details such as the date, voting methods, agenda items, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather information about the meeting where such reports will be discussed and voted on. The document length is 3352 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2025-03-21 Chinese
健民集团杨智独立董事2024年述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of a company, covering the director's duties, attendance at board meetings, audit work, shareholder communications, and other governance activities during the year 2024. It includes extensive information on corporate governance, internal controls, audit committee activities, remuneration, and shareholder engagement. The content is focused on management and board oversight rather than financial results or earnings. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or certification. The document fits best under Board/Management Information (MANG) as it details the independent director's annual work report and governance activities.
2025-03-21 Chinese
健民集团第十届董事会第三十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 33rd meeting of the 10th Board of Directors of 健民药业集团股份有限公司. It includes voting results on various reports and proposals such as the 2024 President's Work Report, 2024 Board Work Report, 2024 Independent Directors' Reports, 2024 Financial Statements and Budgets, Profit Distribution Plan, 2024 Annual Report, Internal Control Evaluation, financing plans, and other governance matters. The document repeatedly states that these reports and proposals will be submitted to the shareholders' meeting for approval and references where the full reports can be found (e.g., Shanghai Stock Exchange website). The document itself is not the full annual report or financial statements but a board meeting resolution announcement summarizing decisions and voting outcomes. It is not a call transcript, earnings release, or a simple announcement of a report publication. It is a formal board/management information disclosure about board meeting decisions and management reports. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4566 characters) and content support this classification with high confidence.
2025-03-21 Chinese
健民集团关于运用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of its own idle funds for cash management through investment in low-risk financial products. It includes details about the investment amount, risk warnings, board approval, and financial impact. The document is a formal public announcement about a financing or capital management activity rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis but focuses on the update about capital usage and related approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3167 characters, which is consistent with an announcement rather than a full report.
2025-03-21 Chinese
健民集团关于2025年度对外担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the expected external guarantee amount for the year 2025. It details the guarantee amounts, the companies involved, financial data of the subsidiaries, the approval process, and risk disclosures. The content focuses on financing guarantees and related risk management, not on financial results, audit opinions, or management changes. It is a formal announcement about financing guarantees and related approvals, which fits best under Capital/Financing Update (CAP). The document length is about 4925 characters, containing substantive details about financing guarantees rather than a brief notice or a report publication announcement. Therefore, the classification is CAP with high confidence.
2025-03-21 Chinese
健民集团2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告摘要" (2024 Annual Report Summary) of 健民药业集团股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2024, including revenue, net profit, assets, and quarterly breakdowns. It also discusses business operations, industry context, management discussion and analysis, and corporate governance elements typical of an annual report. The document length is over 13,000 characters, which is substantial and consistent with a report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification document. Therefore, this document is best classified as an Annual Report (10-K equivalent). FY 2024
2025-03-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.